Gabapentin Enacarbil Market

Gabapentin enacarbil is an anticonvulsant and analgesic drug of the gabapentinoid class, and a prodrug to gabapentin. It was designed for increased oral bioavailability over gabapentin, and human trials showed it to produce extended release of gabapentin with almost twice the overall bioavailability, especially when taken with a fatty meal. Gabapentin enacarbil has passed human clinical trials for the treatment of restless legs syndrome, and initial results have shown it to be well tolerated and reasonably effective.
Gabapentin Enacarbil Market contains market size and forecasts of Gabapentin Enacarbil in global, including the following market information:
Global Gabapentin Enacarbil Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Gabapentin Enacarbil Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Gabapentin Enacarbil companies in 2021 (%)
The global Gabapentin Enacarbil market was valued at 1586.6 million in 2021 and is projected to reach US$ 1783.4 million by 2028, at a CAGR of 1.7% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Capsule Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Gabapentin Enacarbil include Arbor Pharma, Astellas, GlaxoSmithKline, Glenmark Pharma, Pfizer, Depomed, Teva, Mylan and Novartis, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Gabapentin Enacarbil manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Gabapentin Enacarbil Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Gabapentin Enacarbil Market Segment Percentages, by Type, 2021 (%)
Capsule
Tablet
Global Gabapentin Enacarbil Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Gabapentin Enacarbil Market Segment Percentages, by Application, 2021 (%)
Post-Herpetic Neuralgia (PHN)
Restless Legs Syndrome (RLS)
Others
Global Gabapentin Enacarbil Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Gabapentin Enacarbil Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Gabapentin Enacarbil revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Gabapentin Enacarbil revenues share in global market, 2021 (%)
Key companies Gabapentin Enacarbil sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Gabapentin Enacarbil sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Arbor Pharma
Astellas
GlaxoSmithKline
Glenmark Pharma
Pfizer
Depomed
Teva
Mylan
Novartis
Apotex
Sun Pharmaceutical
Aurobindo Pharma
Intas
Amneal
Marksans Pharma
Alkem
Jiangsu Enhua
Jiangsu Hengrui
Sailike Pharma